课题基金 / 基金详情

The role of the EphA1 in the normal epithelial organs and in epithelial tumour progression.

The role of the EphA1 in the normal epithelial organs and in epithelial tumour progression.
EphA1 在正常上皮器官和上皮肿瘤进展中的作用。
批准号:
nhmrc : 290212
负责人:
E/Pr Andrew Boyd
金额:
$37.64万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2004
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2004-01-01 至 2006-12-31

项目摘要

项目成果

E/Pr Andrew Boyd的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Eph family of proteins were initially found to be important in normal development. In humans this corresponds to the first 12 weeks of pregnancy. In parallel with these studies, other work provided evidence of abnormally high levels of these proteins in a number of human cancers. More recent evidence suggests that these proteins have important roles in the maintenance of normal tissues and in non-malignant diseases. This proposal seeks to understand how one of these proteins (EphA1) works in the cells which form the skin, liver, kidneys, breast and prostate. These cells also form the lining of the mouth, stomach, bowel and lungs. Understanding how the EphA1 protein and other members of this family cooperate to control the development and maintenance of these organs will allow us to determine whether this protein might be involved in congenital defects and diseases in these organs (such as kidney failure, cirrhosis of the liver and skin diseases). A second main aim of this project is to explore further the observation that Eph proteins are abnormally highly expressed in a wide rangre of human cancers. This abnormal expression is directly correlated with the tumours spreading throughout the body. EphA1 is abnormally highly expressed in cancers of the bowel, lung, breast and prostate. These are the commonest cancers in man and some of the most difficult to treat. The work proposed asks how EphA1 contributes to the development and progression of these cancers. These results will have very direct implications for the development of therapies which target the EphA1 protein.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EphA3 is a marker of glioma stem/progenitor cells and a potential target for therapy.
Therapeutic development of a novel EphA4 antagonist for spinal cord injuries
  • 批准号:
    nhmrc : 1017308
  • 项目类别:
    NHMRC Development Grants
  • 资助金额:
    $45.82万
  • 财政年份:
    2011
  • 负责人:
    E/Pr Andrew Boyd
  • 依托单位:
国内基金
EphA1/EphrinA1通路调控EPCs归巢肝癌新生血管的分子机制研究
  • 批准号:
    81201953
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    陈钢
  • 依托单位: